Cadence Prevails Against Exela In Generic Ofirmev Row
A Delaware federal judge has ruled against Exela Pharma Sciences LLC and its subsidiaries in favor of Cadence Pharmaceuticals Inc. in a patent infringement suit over plans to market a generic...To view the full article, register now.
Already a subscriber? Click here to view full article